Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin
Open Access
- 1 May 1981
- Vol. 47 (9), 2288-2294
- https://doi.org/10.1002/1097-0142(19810501)47:9<2288::aid-cncr2820470931>3.0.co;2-3
Abstract
In a prospective controlled randomized trial, patients with advanced ovarian carcinoma (FIGO Stage III or IV) were treated with cis‐diamminedichloroplatinum (II), (DDP), alone, DDP and Adriamycin (ADM), or Triethylenethiophosphoramide (ThioTEPA) and methotrexate (MTX). DDP alone produces objective responses in 31% of evaluable patients, ThioTEPA and MTX in 36%. The combination of DDP and ADM produces the best response rate, 80% (.01 <P 2 cm, residual tumors failed to produce their usual adverse effect on prognosis when patients were treated with the two DDP regimens. Patients with poorly differentiated tumors or tumors of unknown grade treated with platinum or DDP‐ADM experienced better survival than similar patients treated with ThioTEPA (P = .01).This publication has 12 references indexed in Scilit:
- Chemotherapy in Gynecologic CancerSurgical Clinics of North America, 1978
- Second trial drugs in ovarian cancerGynecologic Oncology, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Combination chemotherapy with adriamycin andcis-diamminedichloroplatinum in patients with neoplastic diseasesCancer, 1976
- Diamminodichloroplatinum in the Chemotherapy of Testicular TumorsJournal of Urology, 1974
- Diaminodichloroplatinum: A phase I study showing responses in testicular and other tumorsCancer, 1974
- AdriamycinAnnals of Internal Medicine, 1974
- Adriamycin and bleomycin, alone and in combination, in gynecologic cancersCancer, 1973
- Treatment of Ovarian Carcinoma: Possibilities for ProgressNew England Journal of Medicine, 1972
- Cardiovascular alterations in toxemiaAmerican Journal of Obstetrics and Gynecology, 1970